Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACRS 1.22 -0.02(-1.61%)
Will ACRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRS
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACRS
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
H.C. Wainwright Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Announces Sale of OLUMIANT? Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties